Fascinating analysis from Ed Saltzman. In the current environment, it is time for #biotechs to rethink exit strategies and prioritize current resources to derisk commercial #risks, especially for novel/complex modalities. Novel technology platforms should also focus on demonstrating agile #CMC production process to increase incentives for partnering. However, self-commercialization should also be on the table regarding next steps. #drugdevelopment #biotech #investor #partnering #businessdevelopment #riskassessment
Slides from the recent keynote "Biopharma Dealmaking: Time for a Re-Think" I delivered at the Swiss Healthcare Licensing Group meeting in Montreux in May are now available on the Lumanity website. https://lnkd.in/ePi9Vwse This data rich presentation is important viewing for anyone involved with or interested in biotech corp dev strategy but especially for those pre-commercial biotech "sellers" pinning their hopes on a large pharma partnership. The historically unprecedented increase in the number of biotechs reaching or surpassing clinical PoC stage (5 x or greater over past decade) coupled with a limited number of large pharma "buyers" means odds for vast majority of would be sellers are long. Many more of these biotechs should start to see self-commercializing, especially those pursuing advanced therapeutic modalities, such as cell and gene therapy, as more of a "Plan A" than B. And for many of these companies the time to get started is now, not when they are late in P3 or beyond.
